Studies have also suggested the role of gene polymorphisms in the genes encoding TNF, IL-6, and PAD-4 that affect susceptibility to RA [29–31] and the response to TNFI including infliximab, etanercept, adalimumab, and certolizumab pegol [32]. This evidence concerns the gene PADI4 and rheumatoid arthritis.